Radioactive 125I seed implantation in treatment of vein tumor thrombi in patients with hepatocellular carcinoma / 中国介入影像与治疗学

ABSTRACT

Objective: To explore the value of CT-guided radioactive 125I seed implantation for treatment of vein tumor thrombi in patients with primary hepatocellular carcinoma (HCC). Methods: Data of 10 patients with primary HCC complicated with vein tumor thrombi were analyzed retrospectively. Among them, 8 cases combined with portal vein tumor thrombi and 2 cases combined with hepatic vein tumor thrombi. Radioactive 125I seed implantation for vein tumor thrombi was performed. Treatment planning system (TPS) was used to make preoperative plan, and dose verification was performed immediately after operation. The effective rate and local control rate of cancer thrombi were observed up till 6 months after operation. Survival analysis was performed, and intraoperative and postoperative complications were analyzed. Results: 125I seed implantation was successfully completed in all patients. No recurrence of tumor thrombus occurred during post-operation follow-up. The effective rate was 90.00% (9/10), and the disease control rate reached 100% (10/10) 6 months after operation. Postoperative overall survival was 8-36 months. The 1-year and 2-year survival rate was 70.00% and 40.00%, respectively. Intraoperative hepatic hemorrhage and hepatic pain were observed each in 2 cases, while postoperative mild nausea and decreased appetite occurred in 2 cases. No acute and late radiation damage and serious complications occurred. Conclusion: CT-guided radioactive 125I seed implantation is safe and effective for treatment of vein tumor thrombi in patients with primary HCC.